Myelodysplastic Syndromes (MDS) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2026 To 2036

Myelodysplastic Syndromes Market Outlook and Forecast

Thelansis's "Myelodysplastic Syndromes (MDS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2026 To 2036" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Myelodysplastic Syndromes treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Myelodysplastic Syndromes Overview

Myelodysplastic syndromes (MDS), also termed myelodysplastic neoplasms, are clonal bone-marrow disorders in which ineffective blood-cell production causes cytopenias and may progress to acute myeloid leukemia. Symptoms include fatigue from anemia, infections from neutropenia, or bleeding from thrombocytopenia. Diagnosis combines blood counts, marrow examination, cytogenetics, and molecular testing; risk assessment guides care. In lower-risk disease, treatment aims to improve counts and reduce transfusions using supportive care, erythropoiesis-stimulating agents, luspatercept, imetelstat, or lenalidomide for selected del(5q) cases. Higher-risk disease may require azacitidine or decitabine, intensive therapy in selected patients, and allogeneic stem-cell transplantation, the only potentially curative treatment. Responses may be temporary, especially after hypomethylating-agent failure. New combinations and mutation-directed approaches remain under study; TP53-mutated and relapsed disease remain unmet needs.

Key Highlights

• In the United States, MDS incidence cases are projected to increase from 16,886 in 2026 to 18,560 by 2036.
• MDS is a group of bone marrow disorders characterized by ineffective blood cell production and risk of progression to AML.
• Anemia, infections, and bleeding complications contribute to significant disease burden.
• Unmet need remains for therapies that delay disease progression and improve survival.

Market Overview

• The Italy MDS market is projected to grow from $118M in 2026 to $210M by 2036.
• Market growth is driven by:
• Increasing adoption of targeted therapies and novel treatment combinations
• Advances in disease classification and risk-based treatment approaches
• Future growth will depend on therapies that improve durable responses and reduce progression to AML.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2026-2036)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• GlaxoSmithKline
• Kind Pharmaceuticals LLC
• Takeda
• Agios Pharmaceuticals, Inc.
• Bristol-Myers Squibb
• Syntrix Biosystems, Inc.
• Geron Corporation
• Minovia Therapeutics Ltd.
• Novartis Pharmaceuticals
• AbbVie
• Akeso
• Celgene
• GluBio Therapeutics Inc.
• Taiho Pharmaceutical Co., Ltd.
• BioLite, Inc.
• Longbio Pharma
• BeiGene
• Advanced BioDesign
• Beijing InnoCare Pharma Tech Co., Ltd.
• Pharmacosmos A/S
• ARCE Therapeutics, Inc.
• Aprea Therapeutics
• Treebough Therapies
• Otsuka Australia Pharmaceutical Pty Ltd.
• Sumitomo Pharma America, Inc.
• Cullinan Therapeutics Inc.